Skip to main content

Stevens Raymond C's Form 4 filing

Structure Therapeutics Inc.GPCR · filed Jun 12, 2024

Accession no.
0001415889-24-016510
Filed
Jun 12, 2024
Trade date
Jun 10, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stevens Raymond CCIK 0001698149Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 10, 2024Ordinary SharesCConversionDisposed−555,000$0.00$0643,346Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 10, 2024Ordinary SharesCConversionAcquired+555,000$0.00$0185,000Direct
Jun 10, 2024Ordinary SharesSSaleDisposed−555,000$52.80F4−$9,768,0000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The weighted average sale price for the transaction was $52.7965, and the range of prices was $52.43 and $53.075. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)